We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
Read MoreHide Full Article
Accuray Inc. (ARAY - Free Report) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny. The figure was also significantly lower than earnings of a penny in the year-ago quarter.
Total revenue in the third quarter decreased approximately 7.6% year over year to $97 million and missed our estimate of $117 million. The decline was primarily due to lower sales as well as product and channel mix.
Notably, Accuray carries a Zacks Rank #2 (Buy), hinting at probabilities of outperformance in the near term.
Segment Details
Product Revenues: The downside in revenues was more reflected in product revenues that decreased 10.6% to $48 million ($53.7 million in the second quarter). Product revenues in both the U.S. and Japan were significantly above the prior-year quarter. However, China and Europe delivered a sluggish revenue performance in the quarter.
Service Revenues: Revenues at the segment decreased 4.4% to 49.3 million year over year. Per management, the decrease in revenues was primarily due to lower installations.
Gross Order Update: In the reported quarter, gross product orders totaled $83.8 million, compared with $56.4 million in the prior-year quarter. At the end of the quarter, product backlog was $450 million, approximately 21% higher year over year. Gross order performance was favorably impacted by the company’s flagships Radixact Systemand CyberKnife System orders.
Accuray Incorporated Price, Consensus and EPS Surprise
The company’s new TomoTherapy product platform, also known as Radixact, continued to contribute to the company’s top line. The platform gained Japanese regulatory approval (Shonin approval) and is expected to start formal treatments from the fourth quarter.
Onrad, Accuray’s second new product, also provided a modest contribution to gross orders.
Coming to the CyberKnife platform, this represented approximately 50% of gross orders in the quarter, courtesy of its M6 system.
Margin Details
Gross margin (as a percentage of net revenues) contracted 620 basis points (bps) in the third quarter to 36.4%. This was primarily driven by reduced product gross margins.
Product gross margin (as a percentage of product revenues) decreased 650 bps over the prior year to 38%, primarily driven by lower overall unit sales volumes.
Service gross margins in the fiscal third quarter were 34.4%, down 600 bps on a year-over-year basis.
Operating expenses for the quarter were $36.7 million, down 7% on year-over-year basis.
Balance Sheet
Accuray had $84.1 million of cash and investments as of Mar 31, 2017, reflecting a decrease of $24.3 million from Dec 31, 2016.
Guidance
Accuray projects full-year revenues in the band of $380 million to $390 million. This is lower than the previously provided guidance of $410.0 million to $420.0 million.
The company expects 5% increase in gross orders for fiscal 2017. The product system backlog is expected in the band of $445 million to $460 million.
Adjusted EBITDA for fiscal 2017 is anticipated in the range of $22 million to $26 million.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 66%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 32.8%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock recorded a stellar EPS growth rate (last 3–5 years of actual earnings) of almost 22%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
Accuray Inc. (ARAY - Free Report) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny. The figure was also significantly lower than earnings of a penny in the year-ago quarter.
Total revenue in the third quarter decreased approximately 7.6% year over year to $97 million and missed our estimate of $117 million. The decline was primarily due to lower sales as well as product and channel mix.
Notably, Accuray carries a Zacks Rank #2 (Buy), hinting at probabilities of outperformance in the near term.
Segment Details
Product Revenues: The downside in revenues was more reflected in product revenues that decreased 10.6% to $48 million ($53.7 million in the second quarter). Product revenues in both the U.S. and Japan were significantly above the prior-year quarter. However, China and Europe delivered a sluggish revenue performance in the quarter.
Service Revenues: Revenues at the segment decreased 4.4% to 49.3 million year over year. Per management, the decrease in revenues was primarily due to lower installations.
Gross Order Update: In the reported quarter, gross product orders totaled $83.8 million, compared with $56.4 million in the prior-year quarter. At the end of the quarter, product backlog was $450 million, approximately 21% higher year over year. Gross order performance was favorably impacted by the company’s flagships Radixact Systemand CyberKnife System orders.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated Price, Consensus and EPS Surprise | Accuray Incorporated Quote
Other Highlights
The company’s new TomoTherapy product platform, also known as Radixact, continued to contribute to the company’s top line. The platform gained Japanese regulatory approval (Shonin approval) and is expected to start formal treatments from the fourth quarter.
Onrad, Accuray’s second new product, also provided a modest contribution to gross orders.
Coming to the CyberKnife platform, this represented approximately 50% of gross orders in the quarter, courtesy of its M6 system.
Margin Details
Gross margin (as a percentage of net revenues) contracted 620 basis points (bps) in the third quarter to 36.4%. This was primarily driven by reduced product gross margins.
Product gross margin (as a percentage of product revenues) decreased 650 bps over the prior year to 38%, primarily driven by lower overall unit sales volumes.
Service gross margins in the fiscal third quarter were 34.4%, down 600 bps on a year-over-year basis.
Operating expenses for the quarter were $36.7 million, down 7% on year-over-year basis.
Balance Sheet
Accuray had $84.1 million of cash and investments as of Mar 31, 2017, reflecting a decrease of $24.3 million from Dec 31, 2016.
Guidance
Accuray projects full-year revenues in the band of $380 million to $390 million. This is lower than the previously provided guidance of $410.0 million to $420.0 million.
The company expects 5% increase in gross orders for fiscal 2017. The product system backlog is expected in the band of $445 million to $460 million.
Adjusted EBITDA for fiscal 2017 is anticipated in the range of $22 million to $26 million.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 66%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 32.8%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock recorded a stellar EPS growth rate (last 3–5 years of actual earnings) of almost 22%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >>.